Perrigo fourth-quarter profit rose 54%
YORK August 13 morning news, private label OTC drug manufacturers Perrigo Co (PRGO) said fourth-quarter profit rose 54%, 22% revenue growth, partly due to acquisitions, as well as introduction of new products.
Its net profit from a year earlier 32.3 million U.S. dollars, 35 cents a share, to 49.7 million U.S. dollars, 53 cents a share. Excluding one-time items, earnings per share for the quarter rose 71 cents. Revenue rose 22% to 619 million U.S. dollars.
accepted Analysts surveyed by Thomson Reuters on average expected earnings per share for the quarter rose 68 cents, on revenue of 593 million U.S. dollars.
Perrigo said the fourth quarter, the consumer health care sector revenue rose 18% to 481 million U.S. dollars, mainly due to the introduction of new products, sales growth in existing products, as well as its infant formula manufacturers PBM Holdings and the acquisition of Orion Laboratories.
the company's RX Pharmaceuticals revenues grew 72% to 84 million U.S. dollars.
just past the 2010 fiscal year, Perrigo net profit of 224 million U.S. dollars, 2.41 U.S. dollars a share, on revenue of 2.27 billion U.S. dollars. Adjusted earnings per share were 2.83 U.S. dollars.
for the 2011 fiscal year, the company expects adjusted earnings per share from continuing operations profit of 3.40-3.60 dollars, higher than analyst expectations of 3.23 U.S. dollars. (My humble opinion)
